Clinical effects of treatment with omalizumab in patients with asthma

Clinical effects of treatment with omalizumab in patients with asthma - Clinical effects of treatment with omalizumab in patients with asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002765

Enrollment

Registered

2009-11-13

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Injection omalizumab 75-375mg every 2 or 4 weeks subcutaneously. Injection distilled water eveyr 4 weeks subcutaneously.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with asthma symptoms are not controlled well by high-dose of inhaled corticosteroids, and other anti-asthmatic medications 2) Concentration of serum IgE is from 30 to 700 IU/ml and weight from 30 to 150 kg

Exclusion criteria

Exclusion criteria: 1) Patients have hypersensitivity to omalizumab 2) Pregnancy or lactation 3) Patients judged to be inappropriate by doctors

Design outcomes

Primary

Measure	Time frame
Indices of chest CT	—

Secondary

Measure	Time frame
Parameters of pulmonary function Cell counts of induced sputum Scores of quality of life	—

Countries

Japan

Contacts

Public ContactMakoto Hoshino

Atami Hospital International University of Health and Welfare Department of Respiratory Medicine

0557819171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026